US · TBPH
Theravance Biopharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- George Town KY1-1104
- Website
- theravance.com
Price · as of 2024-12-31
$16.79
Market cap 924.77M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.47 | +75.52% |
| Intrinsic Value(DCF) | $4.89 | -70.88% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $429.99 | |||
| 2014 | $19.38 | $716.63 | $343.80 | $0.00 | $0.00 |
| 2015 | $17.70 | $39.95 | $44,630.42 | $0.00 | $0.00 |
| 2016 | $31.28 | $33.09 | $43.66 | $0.00 | $0.00 |
| 2017 | $28.61 | $28.42 | $0.00 | $0.00 | $312.36 |
| 2018 | $22.66 | $50.98 | $7.03 | $0.00 | $0.00 |
| 2019 | $26.12 | $21.65 | $0.00 | $0.00 | $0.00 |
| 2020 | $20.64 | $23.63 | $0.00 | $0.00 | $0.00 |
| 2021 | $9.89 | $22.96 | $0.00 | $0.00 | $39.82 |
| 2022 | $10.22 | $25.75 | $4.04 | $65.26 | $14.74 |
| 2023 | $8.62 | $31.36 | $2.12 | $0.00 | $0.00 |
| 2024 | $9.53 | $29.47 | $1.82 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Theravance Biopharma, Inc.'s (TBPH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.47
- Current price
- $16.79
- AI upside
- +75.52%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4.89
-70.88% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TBPH | Theravance Biopharma, Inc… | $16.79 | 924.77M | +76% | -71% | — | — | -8.25 | 2.65 | 7.23 | -11.10 | -55.01 | 2.65 | 100.00% | -72.92% | -87.63% | -29.04% | -31.64% | -15.33% | 0.28 | -18.44 | 5.02 | 4.89 | -0.31 | 1500.00% | 1212.00% | -5975.00% | -2.55% | -0.36 | -8.00% | 0.00% | 0.00% | 0.67% | -9.09 | -35.98 | 6.63 | -2.07 |
| AVBP | ArriVent BioPharma, Inc. … | $22.97 | 948.23M | — | — | — | — | -8.55 | 2.67 | — | -5.83 | -47.58 | 2.67 | 0.00% | — | — | -39.36% | -469.29% | -36.75% | 0.00 | — | 13.14 | 12.70 | 0.92 | 1797.00% | — | 2573.00% | -10.20% | -4.06 | -349.38% | 0.00% | 0.00% | 0.00% | -4.98 | -6.69 | — | 22.46 |
| BTX | BlackRock Technology and … | $6.57 | 766.79M | +241% | — | — | — | 35.90 | 0.72 | 31.50 | — | — | 0.72 | 100.00% | 87.75% | 87.75% | 1.87% | 1.87% | 1.84% | 0.00 | 2313.25 | — | — | — | -8265.00% | -8113.00% | 2800.00% | 21.63% | — | 14.55% | 14.41% | 517.40% | 21.63% | 35.90 | 4.62 | 31.50 | 31.17 |
| DAWN | Day One Biopharmaceutical… | $10.60 | 1.09B | +166% | +52,842% | — | — | -9.99 | 2.43 | 6.78 | -5.99 | -509.45 | 2.53 | 89.12% | -80.76% | -67.85% | -22.74% | 1066.44% | -19.68% | 0.01 | — | 8.02 | 7.73 | 1.84 | 196.00% | 2060.00% | 2964.00% | -9.71% | -1.71 | 884.82% | 0.00% | 0.00% | 6.71% | -4.96 | -6.09 | 4.01 | 8.31 |
| GERN | Geron Corporation | $1.68 | 1.07B | +294,119% | -54% | — | — | -6.40 | 3.99 | 14.52 | -5.38 | — | 3.99 | 98.37% | -225.64% | -226.73% | -66.09% | 7931.16% | -35.34% | 0.43 | -9.39 | 5.56 | 5.04 | -0.28 | -1562.00% | 3238692.00% | 3009.00% | -19.62% | -2.48 | 10011.32% | 0.00% | 0.00% | 0.00% | -4.79 | -3.80 | 10.82 | -2.06 |
| GLUE | Monte Rosa Therapeutics, … | $17.75 | 1.16B | — | -72% | — | — | -6.50 | 2.12 | 6.25 | -1.96 | — | 2.12 | 89.26% | -107.26% | -96.14% | -36.15% | 142.78% | -19.58% | 0.19 | — | 2.40 | 2.37 | 2.49 | -6274.00% | — | -16048.00% | 8.05% | 0.27 | -66.90% | 0.00% | 0.00% | 21.20% | -1.76 | 3.76 | 1.89 | 0.08 |
| LENZ | LENZ Therapeutics, Inc. | $13.49 | 422.1M | — | — | — | — | -10.13 | 2.47 | — | -5.96 | — | 2.47 | 0.00% | — | — | -89.37% | 72.47% | -34.84% | 0.01 | — | 20.36 | 20.09 | 0.38 | -8471.00% | — | -91.00% | -11.88% | -5.71 | 74.02% | 0.00% | 0.00% | 0.00% | -5.06 | -4.95 | — | 26.23 |
| REPL | Replimune Group, Inc. | $7.65 | 631.68M | — | — | — | — | -3.38 | 2.01 | — | -1.69 | — | 2.01 | 0.00% | — | — | -62.58% | -1380.14% | -47.60% | 0.18 | -33.15 | 7.95 | 7.82 | 0.14 | -525.00% | — | 409.00% | -23.79% | -3.08 | -1049.44% | 0.00% | 0.00% | 4.35% | -1.64 | -2.15 | — | 0.67 |
| TYRA | Tyra Biosciences, Inc. | $33.31 | 1.78B | — | — | — | — | -7.24 | 1.82 | — | -2.80 | — | 1.82 | 0.00% | — | — | -31.60% | -1368.86% | -29.34% | 0.02 | — | 23.81 | 23.53 | 0.83 | -679.00% | — | 3836.00% | -11.25% | -4.78 | -925.54% | 0.00% | 0.00% | 5.54% | -2.79 | -4.13 | — | 17.59 |
| VALN | Valneva SE | $11.09 | 954.23M | +215% | -66% | -82% | — | -34.66 | 2.34 | 2.50 | 14.73 | — | 2.72 | 41.89% | 7.86% | -7.22% | -7.91% | 6.06% | -2.55% | 1.19 | 0.56 | 2.61 | 1.78 | 1.50 | -8836.00% | 1032.00% | -6146.00% | -19.71% | -0.59 | -38.00% | 0.00% | 0.00% | 8.17% | 35.45 | -5.65 | 2.79 | 0.09 |
| VIR | Vir Biotechnology, Inc. | $9.09 | 1.26B | +144% | -52% | — | — | -2.95 | 1.69 | 18.87 | -2.39 | — | 1.75 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -1749.00% | -761.00% | -1257.00% | -30.66% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.17 | -2.57 | 14.85 | 0.63 |
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
- CEO
- Rick E. Winningham
- Employees
- 97
- Beta
- 0.16
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4.89 ÷ $16.79) − 1 = -70.88% (DCF, example).